Global Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Global Asthma Market Outlook
Thelansis’s “Global Asthma Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology,
kidney biopsy cases, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for the 32
markets (North America, Europe, Middle East, Asia Pacific, Africa, South /
Latin America).
Global Asthma Overview
Asthma is
a chronic inflammatory airway disease characterised by variable, reversible
airflow obstruction, bronchial hyperresponsiveness, and airway remodelling,
driven predominantly by Th2-mediated eosinophilic inflammation — with type 2
cytokines IL-4, IL-5, and IL-13 central to its pathobiology — alongside
non-eosinophilic neutrophilic and mixed phenotypes recognising asthma’s
considerable biological heterogeneity. Genetic susceptibility, allergen
sensitisation, respiratory viral infections, occupational exposures, and
obesity interact as key disease determinants. Patients present with episodic
wheeze, dyspnoea, chest tightness, and cough — characteristically worse
nocturnally and with triggers — with spirometry demonstrating reversible
obstructive pattern and bronchodilator responsiveness confirming diagnosis;
fractional exhaled nitric oxide and blood eosinophil counts guide type 2
inflammatory burden assessment. Management follows a stepwise GINA framework
prioritising symptom control and exacerbation prevention; inhaled
corticosteroids remain the therapeutic cornerstone, with long-acting
beta-agonists, leukotriene receptor antagonists, and long-acting muscarinic
antagonists as add-on therapies. Biologic agents — dupilumab, mepolizumab,
benralizumab, and tezepelumab — have transformed severe, refractory type 2
asthma management by targeting specific inflammatory pathways. Allergen
immunotherapy offers disease modification in allergic phenotypes. Regular
review, inhaler technique optimisation, trigger avoidance, and personalised
action plans underpin long-term management; prognosis is generally favourable
with treatment adherence, though severe uncontrolled asthma carries significant
morbidity and mortality risk.
Market Definition:
- North America
(United States, Canada)
- Europe
(Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany,
Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain,
Sweden, Switzerland, United Kingdom)
- Middle East
(Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific
(Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New
Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt,
Nigeria, South Africa, Morocco)
- South / Latin
America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
- *As per
Thelansis’s policy, we ensure that we include all the recent updates
before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across the 32
markets (North America, Europe, Middle East, Asia Pacific, Africa, South /
Latin America)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment